Russel William A, Fu Edouard L, Creon Antoine, Faucon Anne-Laure, Caldinelli Aurora, Bouwmans Pim, Inker Lesley A, Delanaye Pierre, Pottel Hans, Ortiz Alberto, Levey Andrew S, Carrero Juan J
Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, the Netherlands.
Nephrol Dial Transplant. 2025 Aug 11. doi: 10.1093/ndt/gfaf148.
The European Kidney Function Consortium (EKFC) 2021 equation to estimate GFR performs as well or better than the CKD-EPI 2009 equation in predominantly white adult European populations, with less bias and greater accuracy against measured GFR. This study explores how changing from the CKD-EPI to the EKFC equation in a large European health system may impact disease distribution, prognosis and clinical decisions.
We studied over 1.7 million adults in Stockholm undergoing routine care during 2006-2021. We compared eGFR values and reclassification across KDIGO GFR categories when changing from the CKD-EPI to EKFC equation and examined associations of eGFR and reclassification with risk for kidney failure with replacement therapy (KFRT), mortality, and major adverse cardiovascular events (MACE) using Cox models. We also modelled the impact of eGFR equation change on clinical decisions like nephrology referral or medication eligibility/contraindication.
EKFC yielded modestly lower eGFR values than CKD-EPI by a median (IQR) of -4.9 (-8.3 to -2.2) mL/min/1.73m². As a result, CKD G3-G5 prevalence rose from 4.5% to 6.2%. Both equations strongly predicted KFRT, mortality, and MACE. Participants reclassified to lower eGFR categories were older; after adjustment for age, participants had similar risks of mortality and MACE to those not reclassified and a lower risk of KFRT. Changing to the EKFC equation would impact clinical decisions at low eGFR thresholds, such as nephrology referrals (22% higher), eligibility for SGLT2is (39% higher) or contraindication for spironolactone in heart failure (26% higher).
Adopting the EKFC equation in this Northern European health system would modestly lower eGFR estimates, increasing the prevalence of moderate/severe CKD and affecting clinical classification and decisions. eGFR by both equations strongly predicted outcomes, but individuals reclassified to a lower eGFR category by EKFC did not have consistent associations across outcomes.
欧洲肾功能联盟(EKFC)2021年估算肾小球滤过率(GFR)的方程在以白人为主的成年欧洲人群中表现与慢性肾脏病流行病学合作组(CKD-EPI)2009年方程相当或更优,相对于实测GFR偏差更小、准确性更高。本研究探讨在一个大型欧洲医疗系统中从CKD-EPI方程转换为EKFC方程如何影响疾病分布、预后及临床决策。
我们研究了2006年至2021年期间在斯德哥尔摩接受常规护理的170多万成年人。我们比较了从CKD-EPI方程转换为EKFC方程时估算肾小球滤过率(eGFR)值及在KDIGO GFR分类中的重新分类情况,并使用Cox模型研究eGFR和重新分类与肾脏替代治疗肾衰竭(KFRT)风险、死亡率及主要不良心血管事件(MACE)的关联。我们还模拟了eGFR方程变化对诸如肾内科转诊或用药资格/禁忌等临床决策的影响。
EKFC得出的eGFR值略低于CKD-EPI,中位数(四分位间距)为-4.9(-8.3至-2.2)mL/min/1.73m²。结果,慢性肾脏病G3-G5患病率从4.5%升至6.2%。两个方程都能有力预测KFRT、死亡率和MACE。重新分类到较低eGFR类别的参与者年龄更大;在调整年龄后,参与者的死亡率和MACE风险与未重新分类者相似,而KFRT风险更低。转换为EKFC方程会在低eGFR阈值时影响临床决策,如肾内科转诊(高22%)、使用钠-葡萄糖协同转运蛋白2抑制剂(SGLT2is)的资格(高39%)或心力衰竭时螺内酯的禁忌(高26%)。
在这个北欧医疗系统中采用EKFC方程会适度降低eGFR估算值,增加中/重度慢性肾脏病的患病率,并影响临床分类和决策。两个方程的eGFR都能有力预测预后,但因EKFC重新分类到较低eGFR类别的个体在各预后方面的关联并不一致。